Sunil Verma: AstraZeneca’s vision to redefine cancer care

Sunil Verma shared on LinkedIn:

“ I had the pleasure of sitting down with Hannah Moir during ESMO24 to discuss AstraZeneca’s vision to redefine cancer care as part of EMJ’s GOLD podcast series.

We discussed the evolution of Cancer therapies with novel modalities that can offer new options for Cancer patients. We also focused on the importance of biomarkers and patient voice in shared decision making as greater complexity emerges in Cancer therapeutic landscape.

It was a rich conversation and I was glad to share more about AstraZeneca’s vision, including data presented at ESMO24.

Huge thanks to Hannah for having me and to Nabihah D. and EMJ GOLD team for facilitating the interview.

Watch the full interview here.”

Source: Sunil Verma/LinkedIn

Sunil Verma, MD, MSEd, FRCPC, is the Senior Vice Precident, Global Head of Oncology Franchise at AstraZeneca. He was also an Associate Professor at the University of Toronto and Medical Oncologist and Research Lead for the Division of Medical Oncology at Sunnybrook Odette Cancer Centre.

Dr. Verma’s research focuses on breast cancer therapies. As principal investigator for multiple breast cancer trials, including Phase III studies, his research has been published in journals like the New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, and Cancer.